BCDA
NASDAQBioCardia Inc.
BioCardia Inc. (BCDA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for BCDA, including 2 SEC filings, 2 press releases and news items and 1 insider trade. The most recent was published Nov 10, 2026.
Financial highlights
Full financials- Revenue, FY2025
- $0
- Revenue growth
- -100.0%
- Net income, FY2025
- -$8.23M
- Free cash flow, FY2025
- -$7.44M
- Cash
- $4.12M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks62-22%
2026-05-172026-11-08
Mix2790d
- SEC Filings11(41%)
- Other7(26%)
- Insider6(22%)
- Earnings2(7%)
- 13D/G1(4%)
Activity · 52 weeks11260 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by BioCardia Inc.SCHEDULE 13G/A - BioCardia, Inc. (0000925741) (Subject)
- PRBioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026SUNNYVALE, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the third quarter of 2026 by conference call on Thursday, November 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to: https://dpregister.com/sreg/10213286/10535c5b644 Please note that registered participants will receive their dial-in number upon registration. For those who have not r
- SECBioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval ApplicationSUNNYVALE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has completed the process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) concerning the application materials required to obtain regulatory approval in Japan for its CardiAMP Cell Therapy System ("CardiAMP") for the treatment of ischemic heart failure. This milestone represents significant progress toward regulatory approval and commercialization of CardiAMP in Japan, one of the world's largest and most sophisticated cardiovascular medical device mar
- INSIDERPresident and CEO Altman Peter bought $475 worth of shares (500 units at $0.95) (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- PRBioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this QuarterSUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter ("Helix") intended for therapeutic and diagnostic agent delivery. In May 2026, the Company and FDA met and reviewed our initial De Novo pre-submission package. FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns regarding the product’s safety data, performance, or compatibility with general classes of agents. In August 2026, FDA confirmed and
- SECSEC Form 8-K filed by BioCardia Inc.8-K - BioCardia, Inc. (0000925741) (Filer)
- SECSEC Form 8-K filed by BioCardia Inc.8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific MeetingSUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the upcoming presentation of a scientific poster entitled "Cardiac Delivery of Autologous Minimally Processed Cell Therapy in HFrEF: Multicenter, Double Blind RCT (CardiAMP HF II)" at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026. The presentation includes details on the design and scientific support for the CardiAMP™ HF II Study. The objective of the study is to determine efficacy of high dos
- SECBioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ CatheterSUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter ("Helix") for therapeutic and diagnostic agent delivery to the heart. In May 2026, the Company and FDA met and reviewed our initial DeNovo pre-submission. FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns regarding the Helix safety data, device performance, or compa
- INSIDERPresident and CEO Altman Peter bought $1,030 worth of shares (1,000 units at $1.03), increasing direct ownership by 0.26% to 384,885 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $1,995 worth of shares (1,900 units at $1.05), increasing direct ownership by 0.50% to 383,885 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin SubmissionSUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones. CardiAMP® Autologous Cell Therapy for Ischemic Heart Failure BioCardia is working towards a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) in Q4 2026. The Company has recently provided detailed responses to PMDA consultation questions and is working with experienced partners on the Shonin Application, the Quality Management System Application, and Foreign Manufacturer Registration. PM
- SECBioCardia Inc. filed SEC Form 8-K: Other Events8-K - BioCardia, Inc. (0000925741) (Filer)
- SECBioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment ConferenceSUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026. Dr. Altman will provide an update on BioCardia’s progress advancing its CardiAMP® autologous cell therapy toward potential regulatory approval in Japan and the United States, the ongoing CardiAMP HF II pivotal trial, and the Compan
- INSIDERPresident and CEO Altman Peter bought $872 worth of shares (800 units at $1.09), increasing direct ownership by 0.21% to 381,985 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
- PRBioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for ApprovalSUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix). FDA has reviewed and accepted the meeting minutes provided by BioCardia in May 2026 which are now considered final. This ratifies the understanding with FDA that BioCardia shared in its May 8, 2026 press release and 8-K filing. "We intend to submit the follow-on pre-submission for Helix incorporating agency advice this quarter which cou
- SECBioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - BioCardia, Inc. (0000925741) (Filer)
- INSIDERPresident and CEO Altman Peter bought $5,022 worth of shares (5,400 units at $0.93), increasing direct ownership by 1% to 381,115 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- INSIDERPresident and CEO Altman Peter bought $1,748 worth of shares (1,900 units at $0.92), increasing direct ownership by 0.51% to 375,785 units (SEC Form 4)4 - BioCardia, Inc. (0000925741) (Issuer)
- SECBioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioCardia, Inc. (0000925741) (Filer)
BCDA FAQ
10 questionsWhat does BioCardia Inc. do?
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery...What is the latest news on BCDA?
In the last 30 days Quantisnow tracked 7 wire items for BCDA: 2 SEC filings, 2 press releases and news items, 1 insider trade and 1 earnings update. The most recent was published on November 10, 2026.What is BCDA revenue?
BioCardia Inc. (BCDA) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is BCDA profitable?
No. BioCardia Inc. reported a net loss of $8.23M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does BCDA have?
BioCardia Inc. reported $4.12M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does BCDA stock trade?
BioCardia Inc. (BCDA) is listed on NASDAQ.What sector and industry is BCDA in?
BioCardia Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about BCDA?
BioCardia Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $9.00 price target on 2021-12-20. Recent price targets cluster around $9.00.What companies are similar to BCDA?
Notable peers in the same industry include AMGN (Amgen Inc.), EXEL (Exelixis Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare BCDA side-by-side with any of them on Quantisnow.How can I track BCDA on Quantisnow?
Quantisnow aggregates BioCardia Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCDA to receive live email and push alerts on every new disclosure.